Technical Analysis for GLTO - Galecto, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 5.77 | 10.01% | 0.53 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Up | Up |
| Historical GLTO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | 10.01% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 1 ATR | about 6 hours ago |
| Possible Pocket Pivot | about 7 hours ago |
| 60 Minute Opening Range Breakout | about 8 hours ago |
| 1,2,3, Pullback Entry | about 8 hours ago |
| Rose Above Previous Day's High | about 8 hours ago |
Get this analysis on your stocks daily!
- Earnings date: ???
Galecto, Inc. Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Biology Alcohol Inflammation Steatohepatitis Idiopathic Pulmonary Fibrosis Non Alcoholic Fatty Liver Disease Progressive Pulmonary Fibrosis Fibrosis Related Disease Related Diseases Breakthrough Therapy Copenhagen Fibrotic Disease Lectins mTOR Galectin Lung Diseases Myelofibrosis Treatment Of Fibrosis Galectin 3 Galecto Biotech
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.99 |
| 52 Week Low | 4.54 |
| Average Volume | 1,071,258 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 5.48 |
| 20-Day Moving Average | 5.22 |
| 10-Day Moving Average | 5.47 |
| Average True Range | 1.11 |
| ADX | 46.34 |
| +DI | 63.70 |
| -DI | 5.08 |
| Chandelier Exit (Long, 3 ATRs) | 13.08 |
| Chandelier Exit (Short, 3 ATRs) | 7.87 |
| Upper Bollinger Bands | 6.62 |
| Lower Bollinger Band | 3.83 |
| Percent B (%b) | 0.7 |
| BandWidth | 53.39 |
| MACD Line | 0.07 |
| MACD Signal Line | -0.04 |
| MACD Histogram | 0.1155 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.81 | ||||
| Resistance 3 (R3) | 7.83 | 7.16 | 7.47 | ||
| Resistance 2 (R2) | 7.16 | 6.64 | 7.16 | 7.36 | |
| Resistance 1 (R1) | 6.47 | 6.32 | 6.82 | 6.45 | 7.24 |
| Pivot Point | 5.80 | 5.80 | 5.98 | 5.80 | 5.80 |
| Support 1 (S1) | 5.11 | 5.28 | 5.46 | 5.09 | 4.30 |
| Support 2 (S2) | 4.44 | 4.96 | 4.44 | 4.18 | |
| Support 3 (S3) | 3.75 | 4.44 | 4.07 | ||
| Support 4 (S4) | 3.73 |
